Increased Tuberculosis Reactivation Risk in Patients Receiving Immune Checkpoint Inhibitor-Based Therapy

• Published in: The oncologist (Dayton, Ohio) Vol. 29; no. 4; pp. e498 - e506
• Main Authors: Chen, Hsing-Wu, Kuo, Yao-Wen, Chen, Chung-Yu, Chang, Chin-Hao, Wang, Su-Mei, Chien, Ying-Chun, Lu, Wei-Chen, Chen, Jo-Pai, Chang, Cheng-Yu, Wei, Yu-Feng, Chang, Shih-Chieh, Shu, Chin-Chung, Wang, Jann-Yuan, Liao, Wei-Yu, Wang, Hao-Chien, Yu, Chong-Jen
• Format: Journal Article
• Language: English
• Published: US Oxford University Press 04.04.2024
• Subjects: Cancer; Cancer therapies; Care and treatment; Complications and side effects; Drug therapy; Female; Humans; Immune Checkpoint Inhibitors - adverse effects; Immunotherapy; Lung cancer; Lung Neoplasms - drug therapy; Male; Original; Prospective Studies; Retrospective Studies; Risk factors; Tuberculosis; Tuberculosis - chemically induced; Tuberculosis - drug therapy; Tuberculosis - epidemiology; China; latent tuberculosis infection; tuberculosis; immune checkpoint inhibitors

Objective Reports of tuberculosis (TB) during anticancer treatment with immune checkpoint inhibitors (ICIs) are increasing. However, it is not clear whether the use of ICIs is a significant risk factor for TB, including reactivation or latent TB infection (LTBI). Methods To determine the risk of TB...